About the Company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and a Union Army veteran of the American Civil War. As of 2022, Lilly is known for its clinical depression drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine) (2004), and its antipsychotic medication Zyprexa (olanzapine) (1996), although its primary revenue drivers are the diabetes drugs Humalog (insulin lispro) (1996) and Trulicity (dulaglutide) (2014). Lilly's achievements include being the first company to mass-produce the polio vaccine developed by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin (insulin medication), Humalog (insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar (insulin glargine). As of 1997, it was the largest corporation and the largest charitable benefactor in Indiana. In 2009, Lilly pleaded guilty for illegally marketing Zyprexa and agreed to pay a $1.415 billion penalty that included a criminal fine of $515 million, the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution of any kind at the time. As of 2019, the company was ranked 123rd on the Fortune 500. It is ranked 221st on the Forbes Global 2000 list of the largest public companies in the world and 252nd on the Forbes list of America's Best Employers. It is currently recognized as the top entry-level employer in Indianapolis. Lilly is a full member of the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LLY News
What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday
Key Takeaways Eli Lilly is set to report earnings Tuesday as investors and analysts expect weight-loss drug demand to ...
A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1
The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the ...
Eli Lilly's $35 insulin cap could unravel, as $13.5M class action settlement falls apart
Eli Lilly had agreed to cap the price of insulin at $35 per month for 4 years and provide a $13.5 million cash fund, however, ...
Eli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscape
Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility from Nexus Pharmaceuticals ...
As Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify ...
Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street. It's a week jam-packed with notable events, ...
Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week'
Jim Cramer has highlighted upcoming significant events for investors, including earnings from major companies like Apple and Amazon, and key economic indicators such as the Federal Reserve meeting and ...
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market
Lilly recently announced news that could solve a big problem.
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared with our long-term fair value estimate of $500.
Eli Lilly acquires Nexus Pharmaceuticals Pleasant Prairie facility
Indiana-based pharmaceutical company Eli Lilly and Illinois-based sterile manufacturer Nexus Pharmaceuticals, LLC recently ...
Eli Lilly to acquire manufacturing facility from Nexus Pharma
Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable ...
Eli Lilly inks deal to acquire Nexus manufacturing plant in Wisconsin as Mounjaro and Zepbound shortages drag on
Lilly is paying an undisclosed sum to acquire Nexus Pharmaceuticals’ injectable production facility in Pleasant Prairie, ...
Loading the latest forecasts...